Skip to main content

ULTRA-DD

Innovative Medicines Initiative LogoEfpia logoEuropean Commission Research and Innovation logo

Search

  • Overview
    • Objectives and disease focus
    • Deliverables
      • Executive Summary 2020 Report
      • Executive Summary 2019 Report
      • Executive Summary 2018 Report
    • Organisation
      • Scientific Committee
      • Leadership
    • Participants
    • News
    • Contact
  • Tissue Platforms
    • Diseases
    • Cell Assay Datasets
  • Probes
    • Chemical Probes
    • Biological probes
  • Antibodies
  • Structures
  • ChromoHub
  • Publications
Publication partner logo
AstraZeneca logo
Publication partner link
https://www.astrazeneca.co.uk

Demonstration of the utility of DOS-derived fragment libraries for rapid hit derivatisation in a multidirectional fashion.

  • Read more about Demonstration of the utility of DOS-derived fragment libraries for rapid hit derivatisation in a multidirectional fashion.

Kidd, S., Fowler, E., Reinhardt, T., Compton, T., Mateu, N., Newman, H., ... Spring, D. (2020). Demonstration of the utility of DOS-derived fragment libraries for rapid hit derivatisation in a multidirectional fashion. Chemical Science, 11(39), 10792-10801.

Cytokine Profiles in Autoantibody Defined Subgroups of Systemic Lupus Erythematosus.

  • Read more about Cytokine Profiles in Autoantibody Defined Subgroups of Systemic Lupus Erythematosus.

Torell F, Eketjäll S, Idborg H, Jakobsson PJ, Gunnarsson I, Svenungsson E, Trygg J. Cytokine Profiles in Autoantibody Defined Subgroups of Systemic Lupus Erythematosus. (2019) Journal of Proteome Reseach. 18(3):1208-1217.

Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives.

  • Read more about Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives.

Idborg, H., Zandian, A., Sandberg, A. S., Nilsson, B., Elvin, K., Truedsson, L., … Jakobsson, P. J. (2019). Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives. Arthritis research & therapy, 21(1), 62. 

Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-based MDMX Inhibitors.

  • Read more about Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-based MDMX Inhibitors.

Stefaniak, J., Lewis, A. M., Conole, D., Galan, S., Bataille, C., Wynne, G. M., … Huber, K. (2018). Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors. ACS Chemical Biology, 13(10), 2849–2854.

Progress towards a public chemogenomic set for protein kinases and a call for contributions

  • Read more about Progress towards a public chemogenomic set for protein kinases and a call for contributions

Drewry, D. H., Wells, C. I., Andrews, D. M., Angell, R., Al-Ali, H., Axtman, A. D., … Willson, T. M. (2017). Progress towards a public chemogenomic set for protein kinases and a call for contributions. PLoS ONE, 12(8), e0181585.

Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins

  • Read more about Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins

Igoe, N., Bayle, E., Tallant, C., Fedorov, O., Meier, J., Savitsky, P., ... Fish, P. V. (2017). Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins. Journal Of Medicinal Chemistry, 60(16), 6998-7011.

Subscribe to AstraZeneca
The ULTRA-DD project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement n° [115766], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This website reflects only the author’s views and neither IMI nor the European Commission is liable for any use that may be made of the information contained therein.
This website is licensed under a CC-BY licence | Accessibility